All In Biotech

Drug Trial Radar · NCT03277261

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )

Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)

Last checked: Nov 20, 2026Latest source record: Dec 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 549 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

549

Actual

Start

Sep 19, 2017

Primary completion

Jul 23, 2020

Study completion Nov 6, 2020

Sponsor

Lead sponsor
TG Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 11, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study determines the Annualized Relapse Rate (ARR) in participants with RMS after 96 weeks (approximately 2 years) treatment with intravenous (IV) infusion of ublituximab/oral placebo compared to 14 mg oral teriflunomide/IV placebo.

Conditions

  • Relapsing Multiple Sclerosis (RMS)

Interventions

  • UblituximabBiological

    Administered as an IV infusion.

  • TeriflunomideDrug

    Film-coated tablets administered orally.

  • Oral PlaceboDrug

    Administered orally.

  • IV PlaceboDrug

    Administered as an IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Relapse Rate (ARR)Time frame: Up to 96 weeks

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • TG Therapeutics RMS Investigational Trial Site

    Carlsbad, California

  • TG Therapeutics RMS Investigational Trial Site

    Long Beach, California

  • TG Therapeutics RMS Investigational Trial Site

    Pasadena, California

  • TG Therapeutics RMS Investigational Trial Site

    Stanford, California

  • TG Therapeutics RMS Investigational Trial Site

    Miami, Florida

  • TG Therapeutics RMS Investigational Trial Site

    Northbrook, Illinois

  • TG Therapeutics RMS Investigational Trial Site

    Kansas City, Kansas

  • TG Therapeutics RMS Investigational Trial Site

    Detroit, Michigan

  • TG Therapeutics RMS Investigational Trial Site

    Amherst, New York

  • TG Therapeutics RMS Investigational Trial Site

    Westerville, Ohio

  • TG Therapeutics RMS Investigational Trial Site

    Franklin, Tennessee

  • TG Therapeutics RMS Investigational Trial Site

    Knoxville, Tennessee

  • TG Therapeutics RMS Investigational Trial Site

    Dallas, Texas

  • TG Therapeutics RMS Investigational Site

    Round Rock, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.